fool.com
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
The biotech published its final earnings report and business covering 2025. It posted a slightly narrower-than-expected net loss for the fourth quarter.
Shattuck Labs, Inc.STTKNASDAQ
Loading
Latest News
globenewswire.com
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided recent business highlights.
globenewswire.com
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details TD Cowen 46 th Annual Health Care Conference Format: Corporate presentation and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer Presentation Date: March 2, 2026 Time: 9:10 AM ET Location: Boston, MA Webcast link: HERE Leerink Partners 2026 Global Health Care Conference Format: One-on-one investor meetings Participant: Taylor Schreiber, M.D.
defenseworld.net
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $6.20 Consensus PT from Analysts
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) has earned a consensus rating of "Hold" from the seven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the
globenewswire.com
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium, taking place February 12-13, 2026.
defenseworld.net
Shattuck Labs, Inc. (NASDAQ:STTK) Sees Large Growth in Short Interest
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 2,198,677 shares, an increase of 113.8% from the December 31st total of 1,028,366 shares. Approximately 3.9% of the shares of the stock are short sold. Based
fool.com
Why Shattuck Labs Stock Soared in December
An analyst's recommendation upgrade had a major impact on investor sentiment. It's now a buy, according to the pundit.
globenewswire.com
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on December 10, 2025 (the “Grant Date”) to a newly-hired non-executive officer.
benzinga.com
Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy
HC Wainwright upgraded Shattuck Labs Inc. (NASDAQ: STTK) from Neutral to Buy, with a price forecast of $6. The company's lead product candidate, SL-325, is a DR3 antagonist antibody for inflammatory bowel disease (IBD).
globenewswire.com
Shattuck Labs to Participate in Upcoming December Investor Conferences
AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025. Conference Details Conference: Piper Sandler 37th Annual Healthcare Conference Format: Presentation and one-on-one meetings Presenter: Taylor Schreiber, M.D.
globenewswire.com
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D.
seekingalpha.com
Shattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 Transcript
Shattuck Labs, Inc. (NASDAQ:STTK ) The United European Gastroenterology (UEG) Congress UEG Week 2025 October 8, 2025 10:00 AM EDT Company Participants Taylor Schreiber - Co-Founder, CEO & Director Conference Call Participants Yu Fan - Wedbush Securities Inc., Research Division Marla C Dubinsky David De Vries - TR1X, Inc. David Nierengarten - Wedbush Securities Inc., Research Division Conversation Yu Fan Wedbush Securities Inc., Research Division Okay. Good morning, everybody.
zacks.com
What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now?
Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.
globenewswire.com
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that Company management will participate in a panel discussion focused on key takeaways from the United European Gastroenterology Week (UEGW) Conference 2025. The session will be moderated by covering analysts Martin Fan, Ph.D.
zacks.com
Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross?
Shattuck Labs, Inc. (STTK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, STTK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
globenewswire.com
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease —
globenewswire.com
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –
globenewswire.com
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –
globenewswire.com
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –
globenewswire.com
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will participate in a DR3/TL1A focused panel discussion and participate in one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8–9, 2025 in Boston, MA. Conference Details Format: Panel Discussion and one-on-one meetings Session Title: TL1A: Pioneering a New MOA in IBD and Beyond Moderators: Thomas J.